Top Quality ATD Aromatase Inhibitor Male Prohormones

Top Quality ATD Aromatase Inhibitor Male Prohormones

Qiuck Details :

ATD/ 1, 4, 6-Andorstatriene-3, 17-Dione
N ° CAS.: 633-35-2
EINECS: 214-983-0
M. F. : C19H22O2
MW: 282.37678
Point de fusion: 164-165
Essai: 99%
Apparence: poudre cristalline blanche .
Usage : 1-4-6 androstatriene-3-17-dione (AT) is a potent irreversible aromatase inhibitor that inhibits estrogen biosynthesis by permanently binding and inactivating aromatase in adipose and peripheral tissue. It is used to control estrogen synthesis.

La description:

1, 4,6-Androstatrien-3,17-dione (AT) is considered to be a potent irreversible aromatase inhibitor that is useful for inhibiting estrogen biosynthesis by binding and inactivating aromatase in peripheral and adipose tissues in a permanent manner.

ATD is a steroidal aromatase inhibitor, known as a suicidal inhibitor because it permanently binds to the aromatase enzyme.ATD has many names in sports supplements including: 1,4,6 etiollochan-dione, 3, 17- keto- etiochol-trien e, androst-1,4,6-triene-3,17-dione and many others. These all refer to CAS 633-35-
2. ATD is used to control estrogen synthesis and present in some of the over-the-counter muscle enhancing and bodybuilding supplements.

Fonction:

It is used to control estrogen synthesis and present in some of the over-the-counter muscle-enhancing and bodybuilding supplements. It increases testosterone levels in the body in an indirect manner and is therefore considered to be one of the favorite supplement among professional athletes and bodybuilders.
1,4,6-Androstatrien-3,17-dione (AT) offers benefits such as improvements in male fertility, mood levels, shortened recovery in case of burns or severe trauma and stimulation in developing mammals. It is considered to be a more effective anti-aromatase substance than many others and is potent enough to increase testosterone levels in the body without a concomitant reduction of the estrogen levels in men. It may be used for hormone or androgen replacement therapy in men without resulting in a concomitant reduction in endogenous estrogen levels when administered in an oral or transdermal way in dosages ranging from 25-150 mg/jour.